Search
Lestaurtinib
go.drugbank.com/drugs/DB06469InvestigationalCategories: Cytochrome P-450 CYP3A Inhibitors, Heterocyclic Compounds, 1-RingALGRX 1207
go.drugbank.com/drugs/DB06482ExperimentalALGRX 1207 is a topical local anesthetic that acts by binding to the fast sodium channel.
PW2101
go.drugbank.com/drugs/DB06483ExperimentalPW2101 is a beta blocker intended for the treatment of hypertension and angina. … The drug was developed by Penwest Pharmaceuticals and in 2005 the FDA issues a Non-Approval letter due to the degree of kinetic variability of PW2101 observed among individuals.
Enzastaurin
go.drugbank.com/drugs/DB06486InvestigationalEnzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of brain cancer.
Categories: Heterocyclic Compounds, 2-RingMirococept
go.drugbank.com/drugs/DB06492ExperimentalIt is a truncated form of the human Complement Receptor 1 (CR1) linked to a unique Prodaptin™ construct that regulates the over-production of complement at the cell surface, which occurs in inflammation … Mirococept (APT070) is a complement inhibitor currently under development for treatment of rheumatoid arthritis and I/RI.
Synonyms: myristoylated recombinant SCR1-3 of human complement reseptor type IVelafermin
go.drugbank.com/drugs/DB06493InvestigationalVelafermin was investigated as a potential therapy for the prevention and treatment of oral mucositis by fostering the regeneration and repair of the cells lining the gastrointestinal tract. … Velafermin was a novel investigational protein therapeutic, also known as fibroblast growth factor-20 (FGF-20), which promotes both epithelial and mesenchymal cell proliferation in vitro and has demonstrated
Furaprofen
go.drugbank.com/drugs/DB06499ExperimentalSynonyms: alpha-Methyl-3-phenyl-7-benzofuranacetic acidCategories: Heterocyclic Compounds, 2-RingS-8510
go.drugbank.com/drugs/DB06504ExperimentalS-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and mild to moderate senile dementia. It was being codeveloped by Shionogi and GlaxoSmithKline.
Categories: Heterocyclic Compounds, 2-RingMLN2704
go.drugbank.com/drugs/DB06513InvestigationalA Phase 1/2 trial (NCT00070837) evaluated the safety, dosage, and pharmacokinetics of MLN2704 in patients with metastatic androgen-independent prostate cancer.
R-1487
go.drugbank.com/drugs/DB06518ExperimentalSalts: R-1487 hydrochlorideCategories: Heterocyclic Compounds, 1-Ring